Our look is new. Our purpose is the same. Learn more about our brand evolution.
[…] on the development of small molecule therapeutics for the potential treatment of Facioscapulohumeral Muscular Dystrophy ( FSHD). The SLU team is led by Fran Sverdrup, PhD, whose lab has been supported […]
[…] task to update the medical profession, considering that most physicians see only a handful of FSHD patients in their career. The information from that muscular dystrophy lecture in medical school […]
Our new issue of the FSHD Advocate, the first of 2021, is now available online. For those of you who receive our flagship magazine by the postal service, it will […]
[…] product pipeline is championed by the small molecule GBC0905 (Rebastinib) aimed at the treatment of FSHD Type 1 and Type 2. Myocea was spun out of San Diego-based Genea Biocells […]
Our inaugural Los Angeles Walk & Roll to Cure FSHD made the local TV news in Torrance, CA, this week! The event was organized by the Los Angeles chapter of […]
